Business ❯ Finance ❯ Corporate Governance ❯ Shareholder Relations

Tender Offers

Samsung Biologics Launches SFr1.46 Billion Cash Bid for PolyPeptide

The purchase aims to add peptide manufacturing to Samsung's CDMO business to accelerate entry into GLP‑1 therapeutics.

DXL Board Unanimously Urges Shareholders to Reject Zodiac’s $0.82 Tender Offer